These supraventricular tachycardias occur in approximately 1 person per 500 in the United States. 6 Atrioventricular nodal reentrant tachycardia is most common among persons older than 20 years of age ...

Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...

Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

The Agency has specifically requested clarification about the time of data recorded for adverse events in the phase 3 trials. The Food and Drug Administration (FDA) has issued a Refusal to File (RTF) ...

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, ...

Ventricular tachycardia, or V-tach (VT), and supraventricular tachycardia (SVT) are two types of tachycardia. The term “tachycardia” refers to a heart rate of more than 100 beats per minute. The key ...

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...

Shares of Milestone Pharmaceuticals Inc. gained 25.4% in premarket trading on Monday after the company said its experimental treatment for paroxysmal supraventricular tachycardia met the primary ...

According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to ...